Skip to main content
. 2022 Dec 22;7(24):e155147. doi: 10.1172/jci.insight.155147

Figure 1. The effects of C26 colon cancer cells’ implantation on body size, tumor size, muscle mass’ and force.

Figure 1

Analysis of CD2F1 mice with subcutaneous C26 implantations or with PBS were performed. Body weights (A, n = 8–16) and tumor-free body weights (B, n = 8–16) were analyzed every week (2& mice were measured at a 14- to 17-day window, and 4& mice were measured on a 26- to 29-day window). Percentage change in tumor-free body weights were analyzed from day 0 to endpoint (C, n = 8–16). In vivo tumor volume measurements were made using calipers (D, n = 16). Tumor mass (E, n = 7–16) and spleen mass (F, n = 8–16) measurements were also completed. Subcutaneous fat from the inguinal fat depot was weighed (G, n = 10). Grip strength was assessed in all groups (H, n = 10). Evaluations of hind limb muscle wet weights were made in the 2-week cohort (I, n = 8) and 4-week cohort (J, n = 16). Results represent mean ± SD; 2-tailed t tests were used to determine the difference between PBS(2wk) vs. C26(2wk) and PBS (4wk) vs. C26(4wk). One-way ANOVA was used to determine the difference between PBS(4wk) vs. C26(4wk) tumor growth. #P < 0.05 PBS(2wk) vs. C26(2wk); *P < 0.05 PBS(4wk) vs. C26(4wk); ****P < 0.0001 PBS(4wk) vs. C26(4wk).